Streetbeat News

Products Services

THRX

Theseus Pharmaceuticals reported initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced GIST, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 12:30 pm

MRNS

Marinus Pharmaceuticals has received a positive opinion from the European Medicines Agency's CHMP for ZTALMY, an adjunctive treatment for seizures associated with CDKL5 deficiency disorder. The European Commission is expected to make a decision within 67 days.

Portfolio Pulse from Happy Mohamed

May 26, 2023 | 12:15 pm

BMY

Bristol Myers Squibb (BMY) received a positive CHMP opinion recommending approval for Opdivo with chemotherapy as a neoadjuvant treatment for resectable non-small cell lung cancer in patients with tumor cell PD-L1 expression. The European Commission will now review the recommendation.

Portfolio Pulse from Happy Mohamed

May 26, 2023 | 12:14 pm

IMMP

Immutep Limited has published data from Part C of its TACTI-002 Phase II trial, showing promising results for eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma. The treatment was safe and well-tolerated, with a 29.7% response rate and a 12-month overall survival rate of 46.0%.

Portfolio Pulse from Happy Mohamed

May 26, 2023 | 12:10 pm

EFTR

eFFECTOR Therapeutics announced interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib in patients with ER+ metastatic breast cancer. The disease control rate is 74%, and the treatment was generally well tolerated. EFTR shares are up 72.7% at $0.91 during the premarket session.

Portfolio Pulse from Vandana Singh

May 26, 2023 | 12:03 pm

ONFO

Onfolio has completed the development of a generative AI search tool for MightyDeals.com, an e-commerce platform offering discounted design resources.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 12:01 pm

IMAB

I-Mab announced positive results from its Phase 1b/2 study of uliledlimab in combination with toripalimab for treatment-naïve advanced non-small cell lung cancer patients. The study showed a favorable safety profile and an objective response rate of 31.3% regardless of PD-L1 and CD73 expression.

Portfolio Pulse from Vandana Singh

May 26, 2023 | 12:00 pm

AAPL

OnePlus co-founder Carl Pei unveiled the launch timeline and battery details of the highly anticipated Nothing Phone (2), which aims to challenge Apple's iPhone dominance. The device is set to launch globally in July and features a larger 4,700 mAh battery and Snapdragon 8+ Gen 1 chipset.

Portfolio Pulse from Ananya Gairola

May 26, 2023 | 12:00 pm

BMY

Bristol Myers Squibb announced positive results from the TRANSCEND CLL 004 Phase 1/2 study of Breyanzi in adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study showed statistically significant complete response rates and high rates of undetectable minimal residual disease. The company also announced positive results from the Phase 3 COMMANDS study of Reblozyl for anemia in adult patients with myelodysplastic syndromes.

Portfolio Pulse from Vandana Singh

May 26, 2023 | 11:56 am

MRNS

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Ztalmy for the treatment of epileptic seizures, according to Reuters.

Portfolio Pulse from Charles Gross

May 26, 2023 | 11:56 am